Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Target Raised at Citigroup

Sensei Biotherapeutics (NASDAQ:FTH) had its price target hoisted by equities research analysts at Citigroup from $55.00 to $60.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s price target suggests a potential upside of 388.76% from the stock’s previous close.

Several other analysts have also weighed in on FTH. Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a research report on Friday, July 31st. They set an “outperform” rating and a $56.00 target price on the stock. Oppenheimer started coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price objective for the company. Wall Street Zen downgraded Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $56.58.

Sensei Biotherapeutics Stock Down 3.2%

Shares of FTH traded down $0.40 during trading hours on Tuesday, hitting $12.28. 858,135 shares of the company were exchanged, compared to its average volume of 274,071. The business’s fifty day moving average is $27.04. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $42.14. The company has a market capitalization of $317.21 million, a P/E ratio of -0.09 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). Equities analysts anticipate that Sensei Biotherapeutics will post -13.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FTH. State of Wyoming bought a new position in Sensei Biotherapeutics during the 3rd quarter worth $25,000. China Universal Asset Management Co. Ltd. raised its holdings in Sensei Biotherapeutics by 48.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company’s stock worth $150,000 after buying an additional 1,760 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Sensei Biotherapeutics in the second quarter valued at approximately $307,000. Renaissance Technologies LLC increased its stake in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. 10.50% of the stock is currently owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.